

# Abstract# 6742: PV-10 triggers immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma via endoplasmic reticulum stress and autophagy

Sowjanya Thatikonda, Ritu Chaudhary, Yeva Meshkovska, Maria I. Biernacki, Robbert J.C. Slebos, Shari Pilon-Thomas, Antonio L. Amelio, Eric A. Wachter, Christine H. Chung

## Abstract

Head and neck squamous cell carcinoma (HNSCC) are complex, diverse cancers affecting mucosal linings of the upper aerodigestive tract. PV-10 (10% rose bengal sodium) is an investigational immunotherapeutic agent that has promising anti-tumor activity in multiple solid tumor cancer types. However, the role of PV-10 in HNSCCs is unknown. Our *in vitro* findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells. Notably, PV-10 promotes an increase in reactive oxygen species (ROS), leading to a significant rise in late apoptotic cells. Our results suggest that PV-10 induces immunogenic cell death (ICD) in both mEER and MTE-RAS *in vitro* and *in vivo* including the release of Damage-associated molecular pattern molecules (DAMPs) such as HMGB1, ATP, calreticulin, HSP-70, and HSP-90 fostered by ROS-based endoplasmic reticulum (ER) stress and apoptosis. Intralesional (IL) PV-10 injection caused significant tumor regression and a complete response in some mice. These findings hold a promise for potential therapeutic avenues to manage HNSCC.

## Introduction


- HNSCC, affecting the upper aerodigestive tract, ranks as the sixth most prevalent cancer globally. The primary risk factors include human papillomavirus infection (HPV+ HNSCC), or carcinogens found in tobacco and/or the consumption of excessive alcohol (HPV- HNSCC).
- Despite available treatments, recurrent and metastatic HNSCC has poor prognosis, necessitating innovative therapies.
- ICD, a multifaceted cell-death process, involves release of DAMPs upon cellular stress, recruiting DCs and facilitating uptake of tumor antigens.
- PV-10, an IL immunotherapeutic agent, has exhibited ICD and substantial anti-tumor activity in multiple solid tumors, with minimal adverse effects. Its potential in HNSCC remains unclear.
- We evaluated PV-10's role in HNSCC both *in vitro* and *in vivo*. Our findings demonstrate that PV-10 effectively induces release of DAMPs, promoting ICD through activation of ER stress, autophagy, and apoptosis, leading to a significant HNSCC tumor regression.

## Methods and Materials

- Cell viability was assessed using Alamar blue (AB) cell viability assay in murine mEER and MTE-RAS HNSCC tumor cell lines.
- To evaluate the immunomodulatory and apoptotic properties of PV-10, we employed flow cytometry, Immunofluorescence (IF), and luminescence-based assays, DCFDA, Alexa Fluor 488 Annexin V/dead cell apoptosis assay.
- The immunoblotting and multiplex immunohistochemistry (mIHC) were performed to gain insights into the underlying mechanisms of PV-10.


## Results

### PV-10 induces ROS-mediated apoptosis in HNSCC cells




**Figure 1.** (A&B) AB cell viability assay results for mEER and MTE-RAS cells. (C&D) Representative plots of DCFDA fluorescence intensity in mEER and MTE-RAS cells. (E&F) Apoptosis assessment in mEER and MTE-RAS cells using Alexa Fluor 488 Annexin V and DAPI staining.

### PV-10 induces the surface expression of calreticulin in HNSCC cells




**Figure 2.** Flow cytometric analysis was performed in (A) mEER and (B) MTE-RAS cells, while IF was carried out in (C) mEER and (D) MTE-RAS cells.

### PV-10 induces extracellular ATP and HMGB1 release in HNSCC cells




**Figure 3.** Quantification of extracellular ATP levels from (A-C) mEER and (D-F) MTE-RAS as well as HMGB1 levels from (G-I) mEER and (J-L) MTE-RAS at 6h, 24h, and 48h. while IF was carried out in (M) mEER and (N) MTE-RAS cells to analyze HMGB1 expression.

### Surface Expression of HSP-70 and HSP-90 in PV-10-Induced ICD in HNSCC



**Figure 4.** The graphs illustrate the surface HSP-70 expression in (A) early apoptosis (EA) and (B) late apoptosis (LA) of mEER cells, and in (C) EA and (D) LA of MTE-RAS cells. Additionally, the surface HSP-90 expression is shown in (E) EA and (F) LA of mEER cells, and in (G) EA and (H) LA of MTE-RAS cells and IF was carried out to analyze HSP-70 and HSP-80 expressions in (I&J) mEER cells and (K&L) MTE-RAS cells.

### IL PV-10 Injection promotes tumor regression in HNSCC by inducing ER stress, triggering autophagy, and initiating apoptosis.



**Figure 5.** Immunoblotting analysis was performed to evaluate the effect of PV-10 treatment on (A-C) ER stress, autophagy, and apoptosis markers. (D-K) *In vivo* assessment of tumor regression in mEER and MTE-RAS mouse models post IL treatment of PV-10. (L-N) Analysis of ER stress markers, autophagy, and apoptosis pathways in mEER and MTE-RAS tumors

## Conclusions

- PV-10, an IL immunotherapeutic agent, demonstrates significant anti-tumor activity in HNSCC.
- Our *In vitro* studies show PV-10 induces potent ICD in HNSCC cells.
- Our *In vivo* experiments show IL PV-10 lead to substantial tumor regression and complete responses in some mice.
- These findings underscore the significance of PV-10-induced ICD which may offer a novel and promising approach for managing HNSCC and potentially pave the way for improved survival rates and reduced adverse events

## References

- Ang, K. K., et al. (2010). "Human papillomavirus and survival of patients with oropharyngeal cancer." *N Engl J Med* 363(1): 24-35.
- Wachter, E. A., Dees, C., Harkins, J., Fisher, W. G. & Scott, T (2002). "Imaging photosensitizer distribution and pharmacology using multiphoton microscopy. Proceedings of SPIE 4620: 143-147.
- Tabas, I. and D. Ron (2011). "Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress." *Nat Cell Biol* 13(3): 184-190.
- Martins, I., et al. (2014). "Molecular mechanisms of ATP secretion during immunogenic cell death." *Cell Death Differ* 21(1): 79-91.
- Metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade. *Annals of Oncology*.

## Contact information

Correspondence: Dr. Christine Chung, (MD)  
H Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612  
Christine.Chung@moffitt.org

## Acknowledgments

This work has been supported in part by NIH/NIDCR R01DE030123 (to A.L. Amelio), funding from the State of Florida (to A.L. Amelio), the Flow Cytometry Core Facility, Analytic Microscopy Core Facility at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center (P30-CA076292) and the Center for Immunization and Infection Research in Cancer (CIIRC) at the Moffitt Cancer Center. PV-10 was provided by Provectus Biopharmaceuticals and sponsored for poster presentation at AACR conference.